The Use of Topical Corticosteroids for Treatment of Dry Eye Syndrome

Cutolo, Carlo Alberto; Barabino, Stefano; Bonzano, Chiara; Traverso, Carlo Enrico

doi:10.1080/09273948.2017.1341988

Cited by 42 publications

(31 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They are considered highly effective toward the treatment of immune-mediated inflammatory diseases ( 40 ). However, their efficacy is limited to short-term usage (4 weeks or less) ( 41 ) as long term use leads to intraocular pressure and the formation of cataracts ( 40 , 42 ). A combination with anti-inflammation agent (epigallocatechin gallate, EGCG) and mucoadhesive component, hyaluronic acid (HA) was used for the treatment of DES in a rabbit experimental model ( 43 ).…”

Section: Current Therapeutic Strategiesmentioning

confidence: 99%

Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products

et al. 2018

View full text Add to dashboard Cite

Dry eye syndrome (DES) is a multifactorial, frequent, pathology characterized by deficient tear production or increased evaporation of tears and associated with ocular surface alteration and inflammation. It mostly affects, but not exclusively, older individuals and leads to varying degrees of discomfort and decreased quality of life. Although the typical treatments of DES rely on using artificial tears, polyunsaturated fatty acids, integrin antagonists, anti-inflammatory agents, or on performing punctal occlusion, recently, standardized blood-derived serum eye drops (SED) are generating much interest as a new physiological treatment option. The scientific rationale in using SED for treating or releasing the symptoms of DES is thought to lie in its composition in multiple factors that resembles that of tears and contributes to the healing and protection of the ocular surface. This manuscript seeks to provide relevant background information on the management of DES, and on the increasing role that various types of SED or platelet lysates, from autologous or allogeneic origins, are playing in the improved therapeutic management of this pathology. The increasing role played by blood establishments in producing better-standardized SED is also addressed.

show abstract

Section: Current Therapeutic Strategiesmentioning

confidence: 99%

Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Topical agents are thought to be the most effective so far, but some steroid reagents are known to have side effects when they are used for a long period such as elevation of intraocular pressure, cataract formation, infection, etc. 11 Low-level light (laser) therapy (LLLT) has been widely used recently not only to reduce inflammation but also to relieve pain, without any complications. LLLT is noninvasive, non-ablative and only requires a short period of time to treat the symptoms.…”

Section: Introductionmentioning

confidence: 99%

Effects of Low-level Light Therapy at 740 nm on Dry Eye Disease In Vivo

et al. 2019

View full text Add to dashboard Cite

Background and ObjectivesLow-level light therapy (LLLT) is an application of low-power light for various purposes such as promoting tissue repair, reducing inflammation, causing analgesia, etc. A previous study suggested the effect of light emitting diode (LED) light with the wavelength of 740 nm for promoting wound healing of corneal epithelial cells. This current study aimed to confirm the effect of LLLT for managing inflammation of a dry eye disease (DED) mouse model. Materials and MethodsA total of 50C57BL/6 female mice were randomly grouped into 5 groups to compare the effect of LLLT:1) Control group, 2) Only LLLT group, 3) Dry eye group, 4) LLLT in dry eye group, and 5) Early treatment group. DED was induced with 4 daily injections of scopolamine hydrobromide and desiccation stress for 17 days, and LLLT at 740 nm was conducted once every 3 days. To analyze the effect of LLLT on the DED mouse model, tear volume, corneal surface irregularities, and fluorescence in stained cores were measured, and the level of inflammation was assessed with immunohistochemistry. ResultsThe DED mouse model showed significant deterioration in the overall eye condition. After LLLT, the amount of tear volume was increased, and corneal surface irregularities were restored. Also, the number of neutrophils and the level of inflammatory cytokines significantly decreased as well. ConclusionThis study showed that LLLT at 740 nm was effective in controlling the corneal conditions and the degree of inflammation in DED. Such findings may suggest therapeutic effects of LLLT at 740 nm on DED.

show abstract

“…They can suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the cornea epithelium [179]. However, they cause numerous side effects, notably cataract and intraocular pressure evaluation, and increase the risk of infection in long term use [180,181]. Treatment by applying steroidal anti-inflammatory agents has a high potential for inducing many sides effects and hence, steroid-sparing anti-inflammatory agents have also been investigated.…”

Section: Anti-inflammatory Agents (Steroid and Non-steroid)mentioning

confidence: 99%

“…For patients suffering from severe keratoconjunctivitis sicca with eye irritation despite maximum aqueous enhancement therapies, topical ophthalmic steroid is an effective option [181,182]. However, it is important to follow up on steroid-related complications such as increased intraocular pressure and cataract formation, especially if patients were steroid-responders [183].…”

Section: Anti-inflammatory Agents (Steroid and Non-steroid)mentioning

confidence: 99%

Dry Eye Disease: A Review of Epidemiology in Taiwan, and its Clinical Treatment and Merits

Kuo

Lin

Chien

et al. 2019

JCM

View full text Add to dashboard Cite

Dry eye disease (DED) has become common on a global scale in recent years. There is a wide prevalence of DED in different countries based on various ethnicities and environment. DED is a multifactorial ocular disorder. In addition to advanced age and gender, such factors as living at high altitude, smoking, pterygium, prolonged use of consumer electronics or overingesting of caffeine or multivitamins are considered to be the major risk factors of DED. We report the DED epidemiology in Taiwan firstly in this article. According to the pathophysiological factors and changes inthe composition of the tear film in DED, it can be categorized into several subtypes, including lipid anomaly dry eye, aqueous tear deficiency, allergic and toxic dry eye among others. Each subtype has its own cause and disease management; therefore, it is important for ophthalmologists to identify the type through literature review and investigation. The management of DED, relies not only on traditional medications such as artificial tears, gels and ointments, but also newer treatment options such as acupuncture, SYL1001, and nanomedicine therapy. We also conducted a comprehensive literature review including common subtypes and treatment of DED. Clearly, more clinical trials are needed to assess the efficacy and safety of the various treatments and common subtypes of DED.

show abstract

The Use of Topical Corticosteroids for Treatment of Dry Eye Syndrome

Cited by 42 publications

References 73 publications

Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products

Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products

Effects of Low-level Light Therapy at 740 nm on Dry Eye Disease In Vivo

Dry Eye Disease: A Review of Epidemiology in Taiwan, and its Clinical Treatment and Merits

Contact Info

Product

Resources

About